您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Pimozide-d4
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Pimozide-d4
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Pimozide-d4图片
CAS NO:1803193-57-8
包装:1mg
市场价:6033元

产品介绍
Pimozide D4 (R6238 D4) 是一种氘标记的 Pimozide。
Cas No.1803193-57-8
别名R6238-d4
Canonical SMILESFC1=CC=C(C(CCCN2CCC(N3C(NC4=C3C=CC=C4)=O)CC2)C5=C([2H])C([2H])=C(F)C([2H])=C5[2H])C=C1
分子式C28H25D4F2N3O
分子量465.6
溶解度Acetonitrile:Methanol (1:1): soluble
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Pimozide-d4 is an internal standard for the quantification of pimozide by GC- or LC-MS. Pimozide is a dopamine receptor antagonist (Kis = 2.4, 0.3, and 1.8 nM for D2, D3, and D4 receptors, respectively).1 It also binds to eight additional receptors (Kds = 25-3,100 nM for the human receptors) and inhibits the voltage-gated sodium channel Nav1.2 and the voltage-gated potassium channel Kv11.1 (IC50s = 42 and 340 nM, respectively).2,3,4 Pimozide (0.5, 1, and 2 mg/kg) decreases the number of licks and reduces fluid intake of a sweetened solution in rats.5 It decreases the number of threats and attacks and increases immobility time in the neutral arena aggression test, indicating increased passiveness, in male mice when administered at a dose of 0.75 mg/kg for 10 days.6 Formulations containing pimozide have been used in the treatment of Tourette syndrome.

|1. Burstein, E.S., Ma, J., Wong, S., et al. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: Identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. J. Pharmacol. Exp. Ther. 315(3), 1278-1287 (2005).|2. Richelson, E., and Souder, T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 68(1), 29-39 (2000).|3. Roufos, I., Hay, S., and Schwarz, R.D. A structure-activity relationship study of novel phenylacetamides which are sodium channel blockers. J. Med. Chem. 39(7), 1514-1520 (1996).|4. Lau, J.F., Jeppesen, C.B., Rimvall, K., et al. Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides. Bioorg. Med. Chem. Lett. 16(20), 5303-5308 (2006).|5. Xenakis, S., and Sclafani, A. The effects of pimozide on the consumption of a palatable saccharin-glucose solution in the rat. Pharmacol. Biochem. Behav. 15(3), 435-442 (1980).|6. Navarro, J.F., Velasco, R., and Manzaneque, J.M. Acute and subchronic effects of pimozide on isolation-induced aggression in male mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 24(1), 131-142 (2000).